Background This meta-analysis evaluated the real-world effectiveness of
onabotulinumtoxinA (BOTOX®), the first preventive treatment FDA-approved specifically for …

Abstract Introduction OnabotulinumtoxinA (BoNT-A) was proved effective and safe in chronic
migraine (CM) prevention by the Phase III Research Evaluating Migraine Prophylaxis …

Background OnabotulinumtoxinA is approved for the prevention of headache in those with
chronic migraine (CM); however, more clinical data on the risk-benefit profile for treatment …

Background The Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT)
trials demonstrated efficacy/tolerability of onabotulinumtoxinA for headache prevention in …

Objective To examine treatment utilization patterns and safety of onabotulinumtoxinA for the
prophylactic treatment of chronic migraine in routine clinical practice. Background Clinical …

Introduction Numerous medications are used for the preventive treatment of chronic
migraine (CM), including oral treatments, onabotulinumtoxinA (onabotA; BOTOX), and …

Abstract Background The PREEMPT Studies established onabotulinumtoxinA as preventive
treatment for adults with chronic migraine (CM). The purpose of the RE al-life use of …

Objectives: This is the second of a pair of studies designed to evaluate the efficacy and
safety of onabotulinumtoxinA (BOTOX®) for prophylaxis of headaches in adults with chronic …

Background Chronic migraine is a neurological condition with a large individual and
socioeconomic burden of disease. The recently completed Phase III REsearch Evaluating …

Background Migraine is a debilitating neurological disorder that affects 14.1% of the US and
14.7% of the European populations. Chronic migraine (CM) is broadly defined as headache …